Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed, Inc. (Symbol: INSM) is a global biopharmaceutical company headquartered in Bridgewater, NJ, with a mission to transform the lives of patients with serious and rare diseases. The company is committed to developing and bringing to market therapies that significantly improve patient lives, focusing on the entire patient journey from diagnosis and treatment to daily living.
Insmed's flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the US for treating Mycobacterium Avium Complex (MAC) lung disease in adult patients who have limited or no alternative treatment options. ARIKAYCE, utilizing Insmed's proprietary PULMOVANCE® liposomal technology, delivers amikacin directly to the lungs, reducing systemic exposure and associated toxicities. It is administered using the Lamira® Nebulizer System developed by PARI Pharma GmbH, known for its efficiency and portability.
The company’s clinical pipeline includes multiple promising candidates. Notable among them is Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is being developed for treating non-cystic fibrosis bronchiectasis and other neutrophil-mediated diseases. Another significant pipeline product is TPIP (Treprostinil Palmitil Inhalation Powder), an inhaled formulation being evaluated for pulmonary arterial hypertension and other serious pulmonary disorders.
Insmed has demonstrated robust financial performance, with significant revenue growth driven by ARIKAYCE. The company continues to invest heavily in research and development, with plans to expand its product portfolio and market reach globally.
Insmed's strategic partnerships and collaborations play a crucial role in advancing its mission. These include collaborations with PARI Pharma for the Lamira® Nebulizer System and AstraZeneca AB for utilizing their expertise in respiratory diseases.
Recent updates include positive financial results for the third quarter of 2023, robust revenue growth from ARIKAYCE, and significant progress in clinical trials. Noteworthy are the topline results from the Phase 3 ASPEN study for Brensocatib, indicating its potential as a first-in-class treatment. Insmed plans to file a New Drug Application (NDA) with the FDA for Brensocatib by late 2024, aiming for a potential launch in 2025.
The company is also advancing its early-stage research engine, exploring innovative technologies such as artificial intelligence-driven protein engineering and gene therapy, positioning itself at the forefront of biopharmaceutical innovation.
Insmed Incorporated (Nasdaq: INSM) announced its participation in three upcoming virtual investor conferences aimed at discussing the company's developments in biopharmaceuticals. On November 9, 2021, at 10:30 a.m. ET, Insmed will join the Credit Suisse 30th Annual Virtual Healthcare Conference. This will be followed by the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 8:40 a.m. ET, and the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 8:00 a.m. ET. All events will be webcast live and archived for 30 days.
Insmed Incorporated (Nasdaq: INSM) reported Q3 2021 revenue of $46.8 million, up from $43.6 million in Q3 2020. The company experienced a GAAP net loss of $112.7 million or $0.96 per share, widening from a loss of $63.7 million or $0.63 per share year-over-year. Key developments include strong initial uptake of ARIKAYCE in Japan and ongoing clinical trials for brensocatib and TPIP. Insmed ended the quarter with $846.6 million in cash and cash equivalents, positioning it well for future investments and growth.
Insmed Incorporated (Nasdaq:INSM) will release its third quarter 2021 financial results on October 28, 2021. A conference call will follow at 8:30 a.m. ET to discuss the results and offer a business update. Participants can join via phone or through a live webcast on the company's website. Insmed focuses on rare and serious diseases, with its first product being a therapy approved in multiple regions, including the US, Europe, and Japan. The company is also developing investigational therapies in high-need areas.
Insmed announced on October 5, 2021, that it has granted inducement awards to 11 new employees. These awards consist of options to purchase a total of 67,760 shares of common stock at an exercise price of $27.38, the closing price on the grant date. The options feature a ten-year term with a four-year vesting schedule, where 25% vests after the first year and 12.5% every six months thereafter, contingent on continued employment. This initiative is aligned with NASDAQ Listing Rule 5635(c)(4).
On September 3, 2021, Insmed announced the granting of inducement awards to 18 new employees under NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 394,730 shares at an exercise price of $29.13 per share, matching the closing price on September 1, 2021. The options come with a ten-year term and a four-year vesting schedule, with 25% vesting after the first year. Insmed focuses on treating serious and rare diseases with a robust therapy pipeline alongside its first-in-disease product approved in multiple regions.
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on serious and rare diseases, will participate in several upcoming virtual investor events. These include the Citi BioPharma Virtual Conference on September 8, Morgan Stanley Healthcare Conference on September 9, and the H.C. Wainwright Global Investment Conference on September 13, among others. Each session will be webcast and available for 30 days following. Insmed aims to transform patient lives with its therapies, including a first-in-disease treatment for a chronic lung disease.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to eight new employees as part of its hiring strategy. The awards, compliant with NASDAQ Listing Rule 5635(c)(4), included options to purchase 42,320 shares of common stock at an exercise price of $24.13, the closing price on August 2, 2021. The options come with a ten-year term, featuring a four-year vesting schedule. Insmed aims to address serious and rare diseases with its therapies, focusing on unmet medical needs.
Insmed Incorporated (Nasdaq:INSM) reported Q2 2021 financial results, showcasing total revenue of $45.4 million, up from $42.5 million in Q2 2020. The company's net loss widened to $117.3 million or $1.07 per share, compared to a loss of $61.9 million or $0.64 per share year-over-year. Key developments include the launch of ARIKAYCE in Japan, ongoing clinical trials for brensocatib, and advancements in TPIP. Insmed has cash reserves of $928.3 million and plans further investments in product commercialization and clinical activities.
Insmed Incorporated (Nasdaq: INSM) will announce its Q2 2021 financial results on August 5, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Investors can join the call by dialing (844) 200-6205 (domestic) or +44-208-0682-558 (international), with an access code of 711350. The call will also be webcast live on their website. A replay will be available after the call and accessible until September 6, 2021. Insmed is focused on treating serious and rare diseases.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
What is Insmed's primary mission?
What is ARIKAYCE?
What are Brensocatib and TPIP?
Where is Insmed headquartered?
What are Insmed's recent financial highlights?
What are the strategic partnerships of Insmed?
What are the latest developments in Insmed's clinical trials?
What is Insmed's approach to early-stage research?
What is the Lamira® Nebulizer System?
When does Insmed plan to file an NDA for Brensocatib?
